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Objective. Audit of women with invasive cervical cancer (CC) is critical for quality control within screening activities. We analysed
the screening history in the 10 years preceding the study entry in women with and without CC during 2000–2011. Methods. 323
women with CC from six pathology departments in Catalonia (Spain) and 23,782 women with negative cytology were compared.
Age, previous history of cytologies, and histological type and FIGO stage were collected from the pathology registries. Logistic
regression analysis was used to estimate odds ratios (OR) and 95% confidence intervals (CI95%). Results. History of cytology was
registered in 26.2% of CC cases and in 78% of the control women (𝑃 < 0.0001) and its frequency decreased with increasing age.
Compared to women with squamous cell carcinoma, adenocarcinoma cases were significantly more likely to have a cytology within
the 3-year interval preceding cancer diagnosis (OR = 2.6CI 95%: 1.2–5.6) and to have normal cytology results in previous screenings
(OR = 2.4 CI 95%: 1.2–4.5). FIGO II–IV cases were more common among older women (older than 60 years). Conclusions.
Absence of prior screening history was extremely common among CC cases compared to controls. Organized actions to reduce
underscreened women and use of highly sensitive HPV-based tests could be important to reduce CC burden.
1. Introduction
The major cause of cervical cancer (CC) is the persistent
infection with oncogenic types of human papillomavirus
(HPV) [1]. CC is preceded by visible morphological cervical
intraepithelial lesions (CIN) that can be detected through
regular exam of exfoliated cells of the cervix. Although
vaccines to prevent infection with specific oncogenic HPVs
are now available, it will take at least 2-3 decades for their
effects on CC burden to be seen [2].
Meanwhile, adult unvaccinated women remain target for
CC screening. However, to guarantee an adequate population
impact of screening, large population coverage and adequate
follow-up have been fundamental in decreasing incidence
and mortality of CC [3, 4].
In the autonomic region of Catalonia, CC screening is
opportunistic. Efforts to increase CC screening coveragewere
initiated in 2006 within the public sector with the introduc-
tion of new screening protocol [5]. Routine screening with
cervical cytology is recommended in the region to women
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aged 25–65 with a 3-year interval. Cervical cytology coverage
was estimated for the period 2008–2011 to be around 70% if
public as well as private coverage is considered [6, 7]. Every
year, there will be around 378 new cancer cases of CC in the
region implying a lifetime risk of one out of 106 women [8].
As part of quality assessment of the screening activities
in the region, we aimed to monitor screening uptake among
women who have developed invasive CC. For this purpose,
we analysed the screening history in the 10 years preceding
the study entry among women with and without CC who
attended within the Public Health System from a predefined
study area for the period 2000–2011.
2. Patients and Methods
2.1. Data Collection. The study includes all women with an
incident invasive CC diagnosed in six pathology departments
of Catalonia during January 2000 toDecember 2011 (Hospital
General de L’Hospitalet, Corporació Sanitaria Parc Tauĺı,
Hospital Mutua de Terrassa, Consorci Hospitalari de Vic,
Hospital Althaia, and Consorci Hospitalari de Terrassa).
The aforementioned hospitals encompass 2 of the 7 health
counties that compose Catalonia’s Health System.The female
population over the age of 24 in the area was 306,008 women
[9].
A total of 323 newly diagnosed CC cases were identified
during the study period. Information collected from clinical
records during the 10 years prior to CC diagnosis included
history of previous cytologies, time since the last cytology
to cancer diagnosis, age of the patient at time of cancer
diagnosis, and type and stage of CC. We assumed that
cytologies taken within the previous 6 months to the cancer
diagnosis were obtained as part of the diagnostic process and
excluded them for the analysis. Women were categorised as
never screened if there was no record on cervical cytology.
A comparison group consisted of 23,782 women with
a normal cytology retrieved from one of the six pathology
departments and resident in the study area in 2007.Thereafter,
these women are referred to as control group. Information
about the presence or absence of prior cytologies during 10
years before negative cytology and ages of the women were
collected from the same source as the cases.
Theoverall project was approved by the ethical committee
of theCatalan Institute ofOncology. Any information regard-
ing the identification of patients was anonymized before
analysis.
2.2. Screening Tests and Stage of Cervical Cancers. In all
centres, conventional cytology was used. All the cytological
results were classified or adapted if needed, according to the
2001 Bethesda system [10].
CC cases were staged according to the International Fed-
eration of Gynaecology and Obstetrics (FIGO) classification
system [11].
2.3. Statistical Analysis. For thewomenwithCC, information
consisted of histological type, FIGO stage (unknown, I, II,
III, and IV), and registration to previous screening, which
included result of prior cytology (no previous cytology,
normal or abnormal), time since the last previous cytology
(≤3 years and >3 years before cancer diagnostic according
to established 3-year screening interval), and numbers of
previous cytologies (without, 1, or >1 prior cytology). The
large majority of cases were squamous cell carcinoma (SCC)
or adenocarcinoma (ADC). The remaining cases (𝑁 = 15)
were reclassified as follows: three clear cell adenocarcinoma
and one adenoidcystic carcinoma cases were included in
the ADC group while one small cell carcinoma and ten
adenosquamous carcinoma were included in the SCC group.
Data were analysed with and without these rare histological
types and the result was similar in both situations, so they
were included in the analysis. Women with nonevaluable
previous cytology (𝑁 = 2) or missing age were excluded
(𝑁 = 2).
Logistic regression was performed to estimate the odds
ratio (OR) with the corresponding 95% confidential intervals
(CI 95%) of developing ADC or SCC. Adjustment was done
by geographical area and women’s age.
Differences in the presence of cervical cytology in the
previous ten years between the CC cases and the control
group were estimated taking into account the different
age structure of both groups. Proportional differences were
compared using chi-square test. Statistical significance was
defined as 𝑃 < 0.05.
3. Results
Table 1 shows the age distribution and the percentage of
women with prior cytology during the previous 10 years
among 323 CC cases and 23,782 control women.Womenwith
CC were on average 12.6 years older than control women
(54.4 versus 41.9). History of previous cytology was identified
in 78.8% of the control women and in 26.2% of CC cases
(𝑃 < 0.0001). After adjustment for differences in the age
structure, the global use of prior cytology amongCCwas 70%
lower compared to that in controls.
Table 2 describes the age distribution, the period, and the
FIGO stages at diagnosis of the 323 CC cases by histological
type. Overall, 248 (76.8%) of the CCwere SCC and 75 (23.2%)
were ADC. The average age was 54.4 years with a range of
23–96 years. The majority of the CC were diagnosed in the
age range of 40 to 49 years (26.2%). In 40.9% of CC cases,
the cancer stage was unknown. No statistically significant
differences were observed between histological types and the
general characteristics explored.
Women with ADC were significantly more likely to have
had a prior cytology (OR = 2.1 CI 95%: 1.2–3.8), more than
1 previous cytology (OR = 3.2 CI 95%: 1.5–6.5), a cytology 3
years before cancer diagnosis (OR = 2.6 CI 95%: 1.2–5.6), and
a normal cytology (OR = 2.4 CI 95%: 1.2–4.5) as compared to
women with SCC (Table 3).
Age was strongly associated with FIGO stages (𝑃 < 0.05)
(Table 4). Women aged less than 40 years were more likely
to have a stage I CC while stages II–IV were more common
amongwomen aged 60 ormore. Olderwomenwere less likely
to have a prior cytology (82.9% and 79.2% in age groups of
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Table 1: Age and history of previous screening cytology in women with cervical cancer and women with a normal cytology.
Control women Women with cervical cancer∗
𝑃 value
𝑁 = 23,782 % column 𝑁 = 313 % column
Age
<30 years 5.224 22,0% 12 3,9%
<0,0001
30–39 years 5.879 24,7% 56 18,0%
40–49 years 5.426 22,8% 84 27,0%
50–59 years 4.277 18,0% 47 15,1%
60–69 years 2.378 10,0% 41 13,2%
≥70 years 598 2,5% 71 22,8%
With at least one cytology in the last 10 years∗∗
With cytology 18.733 78,8% 82 26,2%
<0,0001
Without cytology 5.049 21,2% 231 73,8%
Age-standardized coverage ratio 0,3
∗There are 2 ages missing.
∗∗10 women with cervical cancer had a prior cytology performed over 10 years ago and they were excluded for the analysis.
Table 2: General characteristics of the study population by histological types.
General characteristics Total




𝑁 = 248 % column 𝑁 = 75 % column
Age∗
<30 years 12 3,7% 8 3,3% 4 5,3% 0,62
30–39 years 56 17,4% 43 17,5% 13 17,3% 0,54
40–49 years 84 26,2% 65 26,4% 19 25,3% 0,54
50–59 years 51 15,9% 43 17,5% 8 10,7% 0,11
60–69 years 41 12,8% 31 12,6% 10 13,3% 0,75
≥70 years 77 24,0% 56 22,8% 21 28,0% 0,64
Year of diagnosis
2000–2003 119 36,8% 92 37,1% 27 36,0% 0,44
2004–2007 73 22,6% 60 24,2% 13 17,3% 0,17
2008–2011 131 40,6% 96 38,7% 35 46,7% 0,37
FIGO stages
Unknown stage 132 40,9% 101 40,7% 31 41,3% 0,70
I 85 26,3% 63 25,4% 22 29,3% 0,78
II 40 12,4% 31 12,5% 9 12,0% 0,49
III 48 14,9% 37 14,9% 11 14,7% 0,56
IV 18 5,6% 16 6,5% 2 2,7% 0,17
∗There are 2 ages missing.
All the variables are adjusted by area and groups of age.
FIGO: International Federation of Gynecology and Obstetrics.
60–69 and ≥70 years, resp.) or to have had a cervical cytology
within an interval longer than 3 years. In the presence of a
previous screening history, women younger than 40 years
old were more likely to have an abnormal cytological result
compared to older women (𝑃 = 0.05). Women with normal
cytology were, on average, older than women with an abnor-
mal cytology (54.6 versus 43.8 years, resp., 𝑃 = 0.003). Most
of the atypical squamous cell of undetermined significance
(ASC-US), atypical squamous cells cannot exclude a high
grade squamous intraepithelial lesion (ASC-H) and atypical
glandular cells of undetermined significance (AGC) results
were diagnosed in the group of women aged 40–49 years
(33.3%) while the low grade squamous intraepithelial lesions
(LSIL) results were mostly diagnosed in women younger
than 40 years (85.7%). About half of the negative cytologies
(56.7%) and 80% of the positive cytologies were performed
within 3 years prior to CC diagnosis (𝑃 = 0.029) (data not
shown). Among all cases, 12 were in women younger than
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Figure 1: Distribution of FIGO stages by time since prior cytology.
30 years of age. Of them, 66.7% did not have any previous
cytology, nearly half of the cases (41.6%) were diagnosed in
stage I, and four were ADC as histological type. Figure 1
shows the distribution of the time since previous cytology to
cancer diagnosis by FIGO stages. Although the differences
were not statistically significant, women without previous
cytology were more likely to be diagnosed at more advanced
stages.
4. Discussion
Our study confirms that lack of CC screening history was
substantially common among women with CC. While 73.8%
of women with CC did not have a previous cervical cytology
record within the Public Health System, less than a quarter
of women attending screening with a normal cytological
result had no previous cytology data in the previous ten
years. The natural history of invasive CC, a disease with long
preneoplastic changes, more than 10 years in the majority of
the cases, generally allows its early detection.Our comparison
with the women attending CC screening having a negative
cytology shows clearly a different behaviour towards screen-
ing. Although our study was not designed to be a case-control
study, it shows, in our opinion, that lack of screening is an
outstanding feature among women with CC.
The proportion of unscreened women among CC cases
in our study was significantly higher than the 23%–68%
range reported by others [12–24]. Organized screening pro-
grams consistently have lower percentages when compared
to opportunistic screening situations [25–27]. van der Aa et
al. [26] from the Netherlands reported a twofold increased
risk of death comparing women with CC screened through
an opportunistic approach with those detected by organized
screening programs. In most studies, advanced age was an
additional factor that contributed to absence of screening
[16, 17, 19, 21, 22]. In our study, women with no prior history
of cytology were significantly older than women with a
history of screening (55.8 versus 51.1 years) and over a third
of CC cases were diagnosed in women aged over 60. It was in
this age group that over 80% of the women had no previous
screening history. A recent study about screening coverage
in Catalonia [7] confirmed the poor screening history of
women aged between 66 and 69 years with only 16% of
them reporting a prior cytology in the 3 years prior to the
evaluation [7].
Advanced age has consistently been associated with
increased disease stages in consistence with our observa-
tions where the cases in stages III-IV were double among
women aged over 65 years compared to women younger
than 40 years old. Most likely, the absence of an adequate
screening history plays a major impact in these observations
although we cannot rule out that a certain proportion of
cases could be newly developed after the end of the screening
recommendations [15, 21, 26]. Efforts to reduce this group
of underscreened women have been recommended [28].
We have now an ongoing program to actively identify this
population [5]. A recent evaluation of this strategy [29]
showed that underscreened women had a high burden of
cervical disease. Attempts to extend these initiatives into an
organized activity are undergoing [30] a randomized trial
inviting thesewomen to participate in the screening program.
In contrast with the above data, the utility of CC screening
in women younger than 30 years old is questionable given
the probability of regression of precancer lesions and the
potential harm of the interventions [31]. In our study, 3.7%
(𝑛 = 12) of the women were younger than 30 years of age.
According to population-based cancer registries, the specific
rate of CC in women aged 20–24 and 25–29 years for the year
2007 was 2.37/100,000 and 5.09/100,000 women, respectively,
with a total specific rate of 1.70/100,000 among those younger
than 30 years old [8]. One study carried out in Canada
[31] among women aged 15 to 29 concluded that CC in
adolescents (15–19 years old) was rare and does not justify
a population-based screening. Castañón et al. [32] reported,
in a study carried out in 1,800 women diagnosed with CC
at ages 20–29 from England, that most cases were detected
withmicroinvasive cancer (stage 1A) with excellent prognosis
and although cancers diagnosed between 20 and 24 years
were more likely to be diagnosed at more advanced stages,
their frequency was rarer (2% of all the cancers diagnosed in
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England in 2010) as the majority of the cancers fell between
the range of 26–29 years (63.2%). Prophylactic vaccination
will likely play an important role in these age groups as it is
expected to reduce the incidence of CC substantially [33].
In the present study, among women with prior cytol-
ogy, 37% had a previous normal cytology in the 3-year
screening interval prior to CC diagnosis. In Andrae et al.
[15], 24% of all cases had developed CC despite having a
normal cytology within the recommended interval but the
percentage increased to 40% for women aged older than 65
years. We could only review a small fraction of previous
cytologies, but, in a second reading, three out of 30 could be
considered to be false negatives, two of them being among
cases with a diagnosis of ADC group and one being with
a SCC, confirming the poor sensitivity of a single cervical
cytology [22, 25, 34, 35].The use of HPV testing is now being
proposed in many settings for its better prediction of CIN2+
cases [22, 35, 36].
It is well recognized that women with ADC have higher
risk of having a previous negative cytology [25, 26, 37–39]. In
our study, women with ADCwere twice more likely to have a
previous negative cytology than women with a SCC. Besides,
of all ADC, 17.8% had a prior cytology within a period not
exceeding 3 years before cancer diagnosis while this pro-
portion was 9.9% in SCC. Glandular lesions can be missed,
especially when they do not involve the transformation zone
but are located higher in the endocervical canal. Despite the
wide use of cervical brushes that have improved the capture
of endocervical cells, the risk of underdetection is likely to
remain. HPV testing as primary screening seems to be highly
recommended to improve overall sensitivity of screening
and in particular for the optimization of adenocarcinoma
diagnosis [20].
In a much lower proportion, CC cases could be
attributable to poor follow-up [25]. In our study, 40% of the
cancers with previous cytology had a result of LSIL/HSIL and
most of them (80% of LSIL and 60% of HSIL) were diagnosed
in a period of 3 years or lower at cancer diagnosis. The
reasons why these women did not have an adequate follow-
up are unknown. In a certain proportion, women refrained
from follow-up suggesting that the adequacy of the message
is probably not optimal [40]. Others have reported that a
potential cause of loss of follow-up is a repeated negative
cytology or negative colposcopy [15, 35], suggesting that a
single negative test at follow-up is not enough to send back
women to regular screening when there is a positive test.
The proportion of ADC and SCC found in our study
did not differ from other studies [12–24]. Cytological results
of ASC-US, AGC and ASC-H were found in 4.4% of SCC
while this percentagewasmore frequent inADCcases (9.3%).
Despite small numbers (3/75), AGCwas only seen in theADC
group and all of them had been diagnosed within the 3-year
screening interval. Cytologies classified as AGC, although
relatively uncommon, are likely to be a reliable marker of
cancer varying the incidence of cases from 0.05% to 2.1 [41]
suggesting that immediate colposcopy referral is probably the
best option for these women [39, 41].
There is much controversy about what is the appropriate
age of stopping screening. A case-control study carried out
by Castañón et al. [42] suggested that women with adequate
negative screening at the age of 50–64 years substantially
reduced their risk of CC at the age of 65 years and older
compared with women who were not screened. However,
the magnitude of that protection decreased with time since
the last screen, recommending exiting the screening only if
the last three tests were all negatives. In our data, 81% of
women aged 65 years or more did not have any previous
cytology registered. Among the 18 women with a previous
cytology, 13 had a negative cytology performed over 3 years
of CC diagnosis and only 4 women had a negative cytology
preceding CC diagnosis within the 3-year screening interval.
Interestingly, 3 of these 4 women were diagnosed with ADC,
in agreement with the poorer sensitivity of cytology in the
diagnosis of glandular lesions as compared to squamous
ones. Our data suggest that the number of CC cases that
occurred in women over the age of 65 when exiting the
screening following the recommendations is likely to be very
small.
4.1. Study Limitations and Strengths. We have been able to
explore screening history amongwomen attending the Public
Health System. It is unknown if women attended within the
private gynaecology sector have a different behaviour and,
thus, we cannot extrapolate our results to them. Our control
group consisted of a large sample of women without CC
diagnosis and normal cytology for the purpose to contrast the
absence of screening history by age group in womenwith and
without CC. We cannot exclude that additional explanations
due to factors other than age could partially explain the huge
difference in screening uptake.
Unfortunately, our data was limited in relation to poor
knowledge on stage of disease. This is explained by the fact
that we used pathology registries and not clinical records
where stage is likely to be more complete.
We could only review the negative previous cytologies for
the period 2000–2007 due to logistic limitations but nomajor
changes have taken place in cervical cytology guidelines in
the region for the recent years.Thus, we think that the percent
of false negative results should be similar across the years
evaluated.
Strengths of this study are that information was reported
by six hospitals covering a predeterminate geographical area.
No differences in the data collected were observed between
them. The control population, despite not being matched
to the cases by year of diagnosis, was composed of 23,782
women, providing a robust indication of the screening uptake
when age adjusted analysis is presented.
5. Conclusions
In summary, the results of this study indicate that lack of
screening is a major limitation in CC prevention. Efforts
to increase population coverage of screening, especially in
older women, in which a high number of nonscreened and
higher stages of cancer were observed, have to be paired
with improving the sensitivity of the principal screening
test for a better CC diagnosis. Use of HPV-based screening
8 BioMed Research International
tests may significantly improve the efficiency of screening
interventions.
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the Agència de Gestió d’Ajuts Universitaris i de Recerca
(Catalan Government, Grants AGAUR 2014SGR1077 and
2014SGR756), from the European Commission (7th Frame-
work Program, Coheahr Project, Grant no. 603019), and from
the Lilly Foundation (Premio Fundación Lilly de Investi-
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[12] J. F. Nygård, M. Nygård, G. B. Skare, and S. Ø. Thoresen,
“Screening histories of women with CIN 2/3 compared with
women diagnosed with invasive cervical cancer: a retrospec-
tive analysis of the Norwegian Coordinated Cervical Cancer
Screening Program,” Cancer Causes and Control, vol. 16, no. 4,
pp. 463–474, 2005.
[13] P. Priest, L. Sadler, J. Peters et al., “Pathways to diagnosis
of cervical cancer: screening history, delay in follow up, and
smear reading,” An International Journal of Obstetrics and
Gynaecology, vol. 114, no. 4, pp. 398–407, 2007.
[14] J. Spayne, I. Ackerman, M. Milosevic, A. Seidenfeld, A. Covens,
and L. Paszat, “Invasive cervical cancer: a failure of screening,”
European Journal of Public Health, vol. 18, no. 2, pp. 162–165,
2008.
[15] B. Andrae, L. Kemetli, P. Sparén et al., “Screening-preventable
cervical cancer risks: evidence from a nationwide audit in
Sweden,” Journal of the National Cancer Institute, vol. 100, no.
9, pp. 622–629, 2008.
[16] A. Herbert, M. Gregory, S. S. Gupta, and N. Singh, “Invasive
cervical cancer audit: a relative increase in interval cancers
while coverage increased and incidence declined,” BJOG, vol.
116, no. 6, pp. 845–853, 2009.
[17] P. G. Lindqvist, C. Hellsten, and A. Rippe, “Screening history
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[32] A. Castañón, V. M. W. Leung, R. Landy, A. W. W. Lim, and
P. Sasieni, “Characteristics and screening history of women
diagnosed with cervical cancer aged 20–29 years,” British
Journal of Cancer, vol. 109, no. 1, pp. 35–41, 2013.
[33] I. M. C.M. de Kok, J. van Rosmalen, K. Rozemeijer, C. Penning,
and M. van Ballegooijen, “How many cervical cancer cases can
potentially be prevented using a more sensitive screening test at
young age?” International Journal of Cancer, vol. 134, no. 2, pp.
460–466, 2014.
[34] K. Nanda, D. C. McCrory, E. R. Myers et al., “Accuracy of the
papanicolaou test in screening for and follow-up of cervical
cytologic abnormalities: a systematic review,” Annals of Internal
Medicine, vol. 132, no. 10, pp. 810–819, 2000.
[35] J. Cuzick, “Routine audit of large-scale cervical cancer screening
programs,” Journal of the National Cancer Institute, vol. 100, no.
9, pp. 605–606, 2008.
[36] M. Arbyn, G. Ronco, A. Anttila et al., “Evidence regarding
human papillomavirus testing in secondary prevention of
cervical cancer,” Vaccine, vol. 30, supplement 5, pp. F88–F99,
2012.
[37] P. Sasieni, A. Castanon, and J. Cuzick, “Screening and adenocar-
cinoma of the cervix,” International Journal of Cancer, vol. 125,
no. 3, pp. 525–529, 2009.
[38] L. T. Gien, M.-C. Beauchemin, and G. Thomas, “Adenocarci-
noma: a unique cervical cancer,” Gynecologic Oncology, vol. 116,
no. 1, pp. 140–146, 2010.
[39] L. Di Bonito and C. Bergeron, “Cytological screening of endo-
cervical adenocarcinoma,” Annales de Pathologie, vol. 32, no. 6,
pp. e8–e14, 2012.
[40] A. Acera, J. M. Manresa, D. Rodriguez et al., “Analysis of three
strategies to increase screening coverage for cervical cancer
in the general population of women aged 60 to 70 years: the
CRICERVA study,” BMC Women’s Health, vol. 14, no. 1, article
86, 2014.
[41] J. P.D.H.Marques, L. B. Costa, A. P.D. S. E. Pinto et al., “Atypical
glandular cells and cervical cancer: systematic review,” Revista
da AssociaçãoMédica Brasileira, vol. 57, no. 2, pp. 234–238, 2011.
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